MCOLN2 and breast carcinoma: Thus, we firstly evaluated the expression of the TRPML1 and TRPML2 channels by Western blot analysis in T98 and U251 GBM, DU145 prostate cancer, 5637 and T24 bladder cancer, and SKBR3 and BT549 breast cancer cell lines, and in the peripheral blood mononuclear cells (PBMCs) used as positive control (Figure 2A).